Ankylosing spondylitis medical therapy: Difference between revisions
Jump to navigation
Jump to search
| Line 11: | Line 11: | ||
** European League Against Rheumatism (EULAR) | ** European League Against Rheumatism (EULAR) | ||
** American College of Rheumatology (ACR)/Spondylitis Association of America (SAA)/Spondyloarthritis Research and Treatment Network (SPARTAN) collaboration | ** American College of Rheumatology (ACR)/Spondylitis Association of America (SAA)/Spondyloarthritis Research and Treatment Network (SPARTAN) collaboration | ||
* Pharmacologic medical therapies for ankylosing spondylitis(AS) include Nonsteroidal anti-inflammatory drugs (NSAIDs), tumor necrosis factor (TNF) blocker, and interleukin 17 (IL-17) inhibitors. | * Pharmacologic medical therapies for ankylosing spondylitis(AS) include Nonsteroidal anti-inflammatory drugs (NSAIDs), tumor necrosis factor (TNF) blocker, analgesics, sulfasalazine,intraarticular injections and interleukin 17 (IL-17) inhibitors. | ||
* | ===== Nonsteroidal antiinflammatory drugs(NSAIDs)''<ref name="pmid16582683">{{cite journal |vauthors=Ardoin SP, Sundy JS |title=Update on nonsteriodal anti-inflammatory drugs |journal=Curr Opin Rheumatol |volume=18 |issue=3 |pages=221–6 |date=May 2006 |pmid=16582683 |doi=10.1097/01.bor.0000218940.04613.cc |url=}}</ref>'' ===== | ||
* The first line treatment for all the patients who are having symptomatic ankylosing spondylitis (AS) are with Nonsteroidal antiinflammatory drugs(NSAIDs). | |||
* 70 to 80 percent patients who are taking NSAIDs report substantial relief of back pain and stiffness. | |||
* Play a crucial role in delaying the progression of ankylosing spondylitis. | |||
==References== | ==References== | ||
Revision as of 20:16, 31 March 2018
|
Ankylosing spondylitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Ankylosing spondylitis medical therapy On the Web |
|
American Roentgen Ray Society Images of Ankylosing spondylitis medical therapy |
|
Risk calculators and risk factors for Ankylosing spondylitis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Pharmacologic medical therapies for ankylosing spondylitis(AS) include Nonsteroidal anti-inflammatory drugs (NSAIDs), tumor necrosis factor (TNF) blocker, and interleukin 17 (IL-17) inhibitors.Ankylosing spondylitis (AS) is a chronic inflammatory disease which is manifested by back pain and gradually to spinal stiffness.While treating the AS patients the primary goal is to maximize long-term health-related quality of life.
Medical Therapy
- Medical therapy for AS is according to the guidelines proposed by [1][2][3]
- Assessment of SpondyloArthritis international Society (ASAS)
- European League Against Rheumatism (EULAR)
- American College of Rheumatology (ACR)/Spondylitis Association of America (SAA)/Spondyloarthritis Research and Treatment Network (SPARTAN) collaboration
- Pharmacologic medical therapies for ankylosing spondylitis(AS) include Nonsteroidal anti-inflammatory drugs (NSAIDs), tumor necrosis factor (TNF) blocker, analgesics, sulfasalazine,intraarticular injections and interleukin 17 (IL-17) inhibitors.
Nonsteroidal antiinflammatory drugs(NSAIDs)[4]
- The first line treatment for all the patients who are having symptomatic ankylosing spondylitis (AS) are with Nonsteroidal antiinflammatory drugs(NSAIDs).
- 70 to 80 percent patients who are taking NSAIDs report substantial relief of back pain and stiffness.
- Play a crucial role in delaying the progression of ankylosing spondylitis.
References
- ↑ Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, Dagfinrud H, Dijkmans B, Dougados M, Emery P, Geher P, Hammoudeh M, Inman RD, Jongkees M, Khan MA, Kiltz U, Kvien T, Leirisalo-Repo M, Maksymowych WP, Olivieri I, Pavelka K, Sieper J, Stanislawska-Biernat E, Wendling D, Ozgocmen S, van Drogen C, van Royen B, van der Heijde D (June 2011). "2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis". Ann. Rheum. Dis. 70 (6): 896–904. doi:10.1136/ard.2011.151027. PMC 3086052. PMID 21540199.
- ↑ Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC, Dijkmans B, Dougados M, Géher P, Inman RD, Khan MA, Kvien TK, Leirisalo-Repo M, Olivieri I, Pavelka K, Sieper J, Stucki G, Sturrock RD, van der Linden S, Wendling D, Böhm H, van Royen BJ, Braun J (April 2006). "ASAS/EULAR recommendations for the management of ankylosing spondylitis". Ann. Rheum. Dis. 65 (4): 442–52. doi:10.1136/ard.2005.041137. PMC 1798102. PMID 16126791.
- ↑ Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS, Smith JA, Borenstein D, Hiratzka J, Weiss PF, Inman RD, Majithia V, Haroon N, Maksymowych WP, Joyce J, Clark BM, Colbert RA, Figgie MP, Hallegua DS, Prete PE, Rosenbaum JT, Stebulis JA, van den Bosch F, Yu DT, Miller AS, Reveille JD, Caplan L (February 2016). "American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis". Arthritis Rheumatol. 68 (2): 282–98. doi:10.1002/art.39298. PMC 5123840. PMID 26401991.
- ↑ Ardoin SP, Sundy JS (May 2006). "Update on nonsteriodal anti-inflammatory drugs". Curr Opin Rheumatol. 18 (3): 221–6. doi:10.1097/01.bor.0000218940.04613.cc. PMID 16582683.